Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 8, Issue 2, Pages 155-158
Publisher
Informa UK Limited
Online
2015-02-20
DOI
10.1586/17474086.2015.1016905
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010
- (2017) Mikkael A. Sekeres Journal of the National Comprehensive Cancer Network
- Current state of prognostication and risk stratification in myelodysplastic syndromes
- (2015) Amer M. Zeidan et al. CURRENT OPINION IN HEMATOLOGY
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
- (2014) Amer M. Zeidan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
- (2014) Amer M. Zeidan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
- (2014) Rebekka K. Schneider et al. CANCER CELL
- Why methylation is not a marker predictive of response to hypomethylating agents
- (2014) M. T. Voso et al. HAEMATOLOGICA
- Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
- (2014) Rafael Bejar et al. JOURNAL OF CLINICAL ONCOLOGY
- The genetic basis of myelodysplasia and its clinical relevance
- (2013) M. Cazzola et al. BLOOD
- Clinical and biological implications of driver mutations in myelodysplastic syndromes
- (2013) E. Papaemmanuil et al. BLOOD
- Current therapy of myelodysplastic syndromes
- (2013) Amer M. Zeidan et al. BLOOD REVIEWS
- TP53mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
- (2013) Austin G. Kulasekararaj et al. BRITISH JOURNAL OF HAEMATOLOGY
- Personalizing Oncology: Perspectives and Prospects
- (2013) John Mendelsohn JOURNAL OF CLINICAL ONCOLOGY
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
- (2013) F Traina et al. LEUKEMIA
- Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
- (2013) A Valencia et al. LEUKEMIA
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
- (2013) T Haferlach et al. LEUKEMIA
- Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
- (2011) Martin Jädersten et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Myelodysplastic syndromes: biology and treatment
- (2008) M. Jädersten et al. JOURNAL OF INTERNAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started